Progressive multifocal leukoencephalopathy
- Cases of PML have occurred in patients with MS who received fingolimod in the post-marketing setting1
- The overall incidence of PML under fingolimod therapy not attributed to previous natalizumab treatment is very rare and the risk remains low
- Beyond the known risk factors for developing PML*, no specific risk factors have yet been established in fingolimod-treated patients

*human polyomavirus JC virus infection, immunsuppresion, immunosenescence etc
**exposure includes both clinical trials and postmarketing experience; postmarketing patient exposure is estimated based on worldwide sales volume
^Cumulative number of patients with non-post natalizumab exposure, post-natalizumab exposure where causal relation with fingolimod cannot be ruled out and insufficient information regarding natalizumab exposure
Case details of 64 patients who developed PML under fingolimod
- Mean age at the time of PML diagnosis was 49 (range 29 - 71) years (56 patients)
- Treatment duration with fingolimod was approximately 5 years (range: 18 to 144 months)
- Based on available ALC information, none exhibited sustained grade 4 lymphopenia (<200 cells/ul)

About PML
About PML
- Progressive multifocal leukoencephalopathy is caused by reactivation of the JC virus, a ubiquitous human papovavirus that is typically acquired during childhood and remains latent in the kidneys and possibly other sites (eg, mononuclear cells, CNS)
- Increasingly, PML is occurring as a complication of immunomodulatory therapy
- Common symptoms/signs include clumsiness, hemiparesis, aphasia, dysarthria, hemianopia and cognitive impairment
- PML is suspected in patients with unexplained progressive brain dysfunction, particularly in those with depressed cell-mediated immunity
- CSF is analyzed for JC viral DNA using PCR; a positive result with compatible neuroimaging findings is nearly pathognomonic
- Supportive management and management of underlying disorders are helpful in managing PML
Suspected or confirmed PML: Get Novartis support
Novartis support
- Novartis can help physicians with the assessment of a suspected PML case, after the adverse event has been reported to the company via standard pharmacovigilance processes
- Subsequently, there is access to an external expert MRI service and Novartis has constituted an external PML adjudication panel for case evaluation
- If a second opinion on an MRI with atypical findings/suspicion of PML is requested, Novartis can support obtaining this through a MRI expert center (MIAC), University Hospital Basel, Switzerland. Novartis will not have access to the MRI and will only receive a report
- In addition, Novartis can support logistics for shipment of CSF samples for testing for presence of JCV DNA (PCR) by Unilabs A/S, Denmark and by Quest in the US. In this case, both the physician and Novartis receives the report

Last updated: November 2023. The page will be updated once a year.